Tuesday, 07 Apr 2020

You are here

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.

A total of 448 active RA patients were enrolled in a 24 week trial if they had an inadequate response or intolerance to 1 or more biologic disease-modifying antirheumatic drugs, were maintained on their background conventional synthetic DMARDs (csDMARDs). Patients were randomized to either daily filgotinib, 200 mg (n = 148); filgotinib, 100 mg (n = 153); or placebo (n = 148). The primary endpoint was an ACR20 response at week 12. 

Week 12 outcomes showed filgotinib (FIL) to be significantly superior to placebo, with ACR20 responses:

  • FIL 200 mg = 66.0%
  • FIL 100 mg = 57.5%
  • PBO = 31.1%; (both P < .001),

Even in patients who failed 3 or more prior biologic agents, significant ACR20 responses were achieved with FIL 200 mg (70.3%) and FIL 100 mg (58.8%) compared with PBO treated patients (17.6%).

Common adverse events (in 5-10%) included nasopharyngitis, headache, and upper respiratory infections.

There were 4 cases of herpes zoster cases, 1 retinal vein occlusion and no reports of tuberculosis, opportunistic infections, malignancies, gastrointestinal perforations, or deaths.

This is one of the pivotal drug development trials for filgotinib in RA. Gilead is partnering with Galapagos in developing filgotinib for use in RA and is planning to file for FDA approval later this year.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR Infusion Guidance During COVID-19 Crisis

The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.

Infusions in the Time of Coronavirus

As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week. One of the few good things to come out of this crisis is that we may learn that in-person visits are not as critical as we thought, which may in turn help our specialty’s access issues.

Earlier Anakinra Initiation Warranted in Still's Disease

An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK). 

A total of 141 AOSD patients were retrospectively studied.

Overall, they found no differences in efficacy if ANK was started within 6 (or 12 mos) vs. thereafter.  

Switching Biologics in JIA

While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.